Recently affected by the financial crisis, Europe and the United States pharmaceutical market has failed. Facing the fast-growing Chinese market, Japan's leading pharmaceutical companies have changed their business strategies, vigorously increased their efforts to enter the market, and focused on opening up China's pharmaceutical consumer market. A number of Japanese pharmaceutical companies plan to expand their sales in China by 2-3 times in 2015.
Takeda Pharmaceutical plans to expand the number of pharmaceutical representatives in China from the current 1200 to 2,000, reaching the same scale as Japan, and at the same time developing six new drugs for the treatment of osteoma, diabetes and hypertension in China in the next five years. Sales in China increased from 22 billion yen in 2012 to 50 billion yen in 2015. Eisai Pharmaceuticals currently sells about 16 kinds of drugs in China. The main products are medicines for treating Alzheimer's disease, neuropathy, etc. Drugs for Hepatitis B, breast cancer, and digestive system will be added in the future to increase the variety of drugs. In 20 categories, sales in China will increase to 3 times the current level by 2015, reaching a scale of 45 billion yen. First Sankyo Pharmaceutical has acquired the right to sell imported drugs in China through the acquisition of Shanghai Xinshengyuan. In the future, it will also sell its own antibacterial and high blood pressure drugs, and will also distribute other companies' new drugs and generic drugs for the needs of China. Sales in China will increase from 10 billion yen in 2011 to 360 yen in 2015. Astellas Pharmaceuticals plans to launch Vesicare, a leading drug in urinary system diseases such as urinary incontinence and urinary incontinence in China, and expand sales in China from 180 yen in 2012 to 2015. 40 billion yen scale.
Pv6 10s17c Ac Compressor Chrysler Voyager,10s17c Ac Compressor,10s17c Ac Compressor Chrysler Voyager
Kasen Auto Air Condition Parts Co., Ltd. , http://www.gdclutches.com